Aryl hydrocarbon receptor signaling in the pathogenesis of necrotizing enterocolitis
Aryl hydrocarbon receptor signaling in the pathogenesis of necrotizing enterocolitis
批准号:
9220912
负责人:
MISTY L GOOD
金额:
$7.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-04-01 至 2019-03-31
关键词:
AdultAffectAnti-Inflammatory AgentsAnti-inflammatoryApoptosisAryl Hydrocarbon ReceptorAttenuatedAwardBreast FeedingCD4 Positive T LymphocytesCell Culture TechniquesCell ProliferationCell SeparationCellsClinicalDataDevelopmentDietDiet ModificationDiseaseEndotoxemiaEnteralEnterocytesEpithelialFlow CytometryFormula supplementationFutureGastrointestinal DiseasesGoalsGrowthHistologyHomeostasisHost DefenseHost Defense MechanismHumanHuman MilkHypoxiaImmunohistochemistryInfantInfant MortalityInfant formulaInflammatoryInflammatory ResponseInflammatory disease of the intestineInterleukin ReceptorInterleukin-17IntestinesKnowledgeLymphoid CellMediatingModelingMucosal ImmunityMusNatural ImmunityNatural regenerationNecrosisNecrotizing EnterocolitisNeonatalNutritionalOrgan failureOutcomePathogenesisPathogenicityPlayPremature InfantPrevention strategyProductionPropertyProphylactic treatmentQuantitative Reverse Transcriptase PCRReceptor SignalingRecombinant InterleukinsResearchRoleSeveritiesSignal PathwaySignal TransductionStem cellsSurvival RateT-LymphocyteTestingTherapeuticUnited StatesUnited States National Institutes of HealthWound Healingaryl hydrocarbon receptor ligandbasecell typecytokinedefense responsedesignhigh riskinterleukin-22intestinal epitheliumintestinal homeostasismortalitymouse modelnovelnutritional supplementationpreventresponsetherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease affecting up to 10% of premature
infants and characterized by an interleukin (IL)-17-driven uncontrolled inflammatory response. The goals of the
proposed research are to identify the innate host defense responses in NEC pathogenesis and interrogate how
these responses can be modified or prevented through dietary modifications. We have shown that breast milk
mediates protection against NEC by inhibiting the pro-inflammatory signaling in the intestinal epithelium and
we seek to determine the components of breast milk that mediate this anti-inflammatory effect. We now show
that breast milk contains anti-inflammatory aryl hydrocarbon receptor (AhR) ligands, which have been shown to
be critical for maintaining gut homeostasis by inducing expansion of innate lymphoid cells (ILC) and protective
T helper (Th22) cells via IL-22 production. IL-22 signaling plays a critical role in attenuating intestinal
inflammation, gut barrier function and promoting wound healing by facilitating intestinal stem cell regeneration.
Importantly, these findings highlight the therapeutic potential of enhancing IL-22 production to attenuate pro-
inflammatory responses seen in NEC. Therefore, we hypothesize that IL-22 producing cells play a
protective role in NEC and that nutritional supplementation with AhR ligands will naturally induce
intestinal IL-22 production, and inhibit the pathogenic IL-17 responses seen in NEC. To test this
hypothesis, we will use our experimental NEC model and an ex vivo model of intestinal stem cell isolation and
culture to pursue the following specific aims: Aim 1: To investigate the role of IL-22 producing cells in NEC
pathogenesis. Aim 2: To determine the role of AhR signaling in NEC pathogenesis. These studies will
advance our understanding of the signaling pathways involved in the pathogenesis of NEC and test the novel
preventative nutritional strategy of manipulating anti-inflammatory cytokine production with dietary AhR ligands.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neonatal gut-on-a-chip platform for high content drug testing and precision medicine
-
批准号:10594705
-
项目类别:
-
资助金额:$53.81万
-
财政年份:2022
-
负责人:MISTY L GOOD
-
依托单位:
Neonatal gut-on-a-chip platform for high content drug testing and precision medicine
-
批准号:10491072
-
项目类别:
-
资助金额:$59.01万
-
财政年份:2022
-
负责人:MISTY L GOOD
-
依托单位:
Neonatal gut-on-a-chip platform for high content drug testing and precision medicine
-
批准号:10674890
-
项目类别:
-
资助金额:$60.36万
-
财政年份:2022
-
负责人:MISTY L GOOD
-
依托单位:
Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitis
-
批准号:10704229
-
项目类别:
-
资助金额:$58.99万
-
财政年份:2021
-
负责人:MISTY L GOOD
-
依托单位:
Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitis
-
批准号:10577705
-
项目类别:
-
资助金额:$64.2万
-
财政年份:2021
-
负责人:MISTY L GOOD
-
依托单位:
Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitis
-
批准号:10316733
-
项目类别:
-
资助金额:$68.7万
-
财政年份:2021
-
负责人:MISTY L GOOD
-
依托单位:
Modulation of the Intestinal Immune Response in Necrotizing Enterocolitis
-
批准号:10543597
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2018
-
负责人:MISTY L GOOD
-
依托单位:
Modulation of the Intestinal Immune Response in Necrotizing Enterocolitis
-
批准号:10468084
-
项目类别:
-
资助金额:$34.57万
-
财政年份:2018
-
负责人:MISTY L GOOD
-
依托单位:
Modulation of the Intestinal Immune Response in Necrotizing Enterocolitis
-
批准号:10001502
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2018
-
负责人:MISTY L GOOD
-
依托单位:
Novel Anti-Inflammatory Properties of Breast Milk in Necrotizing Enterocolitis
-
批准号:8820360
-
项目类别:
-
资助金额:$14.68万
-
财政年份:2014
-
负责人:MISTY L GOOD
-
依托单位:
Novel Anti-Inflammatory Properties of Breast Milk in Necrotizing Enterocolitis
-
批准号:9391736
-
项目类别:
-
资助金额:$12.8万
-
财政年份:2014
-
负责人:MISTY L GOOD
-
依托单位:
Novel Anti-Inflammatory Properties of Breast Milk in Necrotizing Enterocolitis
-
批准号:9418041
-
项目类别:
-
资助金额:$14.63万
-
财政年份:2014
-
负责人:MISTY L GOOD
-
依托单位:
海外基金